Literature DB >> 20600355

Gastrin stimulates the VEGF-A promotor in a human colon cancer cell line.

Mark Ellrichmann1, Peter R Ritter, Henning Schrader, Wolfgang E Schmidt, Juris J Meier, Frank Schmitz.   

Abstract

INTRODUCTION: Hypergastrinemia has been observed in patients suffering from colorectal cancer. Vascular endothelial growth factor (VEGF) is known to play a pivotal role in tumour growth. Therefore, we addressed whether gastrin-17-gly and gastrin-17-amide regulate VEGF-A-gene and protein expression.
MATERIALS AND METHODS: Colo-320-cells were stably transfected with a VEGF-Luciferase-reporter gene. Luciferase activity was assessed after stimulation with various gastrin concentrations. Relevant promotor elements were identified by deletion analyses. VEGF protein levels in culture supernatants were quantified by ELISA.
RESULTS: VEGF-A stimulation with gastrin induced a dose- and time-dependent stimulation of luciferase activity. The greatest activities were found 6h after stimulation at concentrations of 10(-)(6)mmol/l. VEGF-promotor expression resulted in significantly (p<0.05) increased VEGF-A protein secretion. These effects were restricted to gastrin-17-amide.
CONCLUSION: Gastrin-17-amide enhances VEGF-A gene and protein expression in Colo320 cells stably transfected with a wild-type CCK-B/gastrin receptor. The induction of VEGF-A transcription and translation may contribute to the carcinogenic effects of gastrin observed in clinical studies. Therefore, CCK-B receptor antagonists may represent a treatment strategy in patients with colorectal cancer.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20600355     DOI: 10.1016/j.regpep.2010.06.004

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  5 in total

1.  Role of ERK-MAPK signaling pathway in pentagastrin-regulated growth of large intestinal carcinoma.

Authors:  Jia-Ding Mao; Pei Wu; Jian-Xiong Huang; Jian Wu; Guang Yang
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

2.  Somatic mutations in CCK2R alter receptor activity that promote oncogenic phenotypes.

Authors:  Melinda D Willard; Mary E Lajiness; Isabella H Wulur; Bo Feng; Michelle L Swearingen; Mark T Uhlik; Kenneth W Kinzler; Victor E Velculescu; Tobias Sjöblom; Sanford D Markowitz; Steven M Powell; Bert Vogelstein; Thomas D Barber
Journal:  Mol Cancer Res       Date:  2012-04-19       Impact factor: 5.852

3.  Vaccine against gastrin, a polyclonal antibody stimulator, decreases pancreatic cancer metastases.

Authors:  Nicholas Osborne; Rebecca Sundseth; Martha D Gay; Hong Cao; Robin D Tucker; Sandeep Nadella; Shangzi Wang; Xunxian Liu; Alexander Kroemer; Lynda Sutton; Allen Cato; Jill P Smith
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-08-21       Impact factor: 4.052

4.  The duration of gastrin treatment affects global gene expression and molecular responses involved in ER stress and anti-apoptosis.

Authors:  Linn-Karina M Selvik; Christina S Fjeldbo; Arnar Flatberg; Tonje S Steigedal; Kristine Misund; Endre Anderssen; Berit Doseth; Mette Langaas; Sushil Tripathi; Vidar Beisvag; Astrid Lægreid; Liv Thommesen; Torunn Bruland
Journal:  BMC Genomics       Date:  2013-06-28       Impact factor: 3.969

5.  Mass Spectrometry-Based (GeLC-MS/MS) Comparative Proteomic Analysis of Endoscopically (ePFT) Collected Pancreatic and Gastroduodenal Fluids.

Authors:  Joao A Paulo; Vivek Kadiyala; Peter A Banks; Hanno Steen; Darwin L Conwell
Journal:  Clin Transl Gastroenterol       Date:  2012-05-03       Impact factor: 4.488

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.